Establishment of a stability indicating HPLC method for dronedarone hydrochloride in tablets and in cyclodextrin inclusion complexes: application to degradation kinetic studies
- 3 Downloads
The stability indicating HPLC method for the determination of dronedarone (DRO) hydrochloride in tablets and in inclusion complexes with cyclodextrin was carried out on a C18 column using a buffer solution (0.3% glacial acetic acid; pH 4.9) and acetonitrile (35:65, v/v) as mobile phase. The method validation according to ICH guidelines demonstrated acceptable results. Dronedarone was exposed to stress conditions, and drug-degradation kinetics was studied. Additionally, the degraded samples were analyzed by mass spectrometry and the preliminary toxicity against 3T3 cells was also determined. The results obtained evidenced that dronedarone degradation kinetics in alkaline conditions followed first-order reaction and that inclusion complexation with cyclodextrin reduced its chemical degradation. Among the samples exposed to stress conditions, only the photodegraded samples presented cytotoxic effects. Moreover, assay results were compared to a previously validated micellar electrokinetic chromatography method, showing non-significant difference (p > 0.05). The combination of HPLC, mass spectrometry and cytotoxicity study could be an important tool for the screening of DRO pharmaceutical forms, improving quality and safety in the development of novel drug delivery systems.
KeywordsCyclodextrin In vitro cytotoxicity Degraded samples Dronedarone High-performance liquid chromatography Inclusion complex
This study was supported by the Brazilian National Council for Scientific and Technological Development (CNPq) [Grants 401069/2014-1 and 447548/2014-0] and CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior).
Compliance with ethical standards
Conflict of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
- Ahirrao VK, Patil CS, Bembalkar SR, Katariya MV, Sonnekar VS, Marathe RP, Nawale RB, Pawar RP (2012) Stress degradation studies of dronedarone in pharmaceutical dosage form by a validated stability-indicating LC method. J Chil Chem Soc 57:1272–1276. https://doi.org/10.4067/S0717-97072012000300016 CrossRefGoogle Scholar
- Australian Public Assessment Report for Dronedarone Hydrochloride prepared by the Department of Health and Ageing (2010) Therapeutic Goods Administration (TGA), Australian Government. https://www.tga.gov.au/sites/default/files/auspar-multaq.pdf. Accessed 6 Jan 2017
- Food and Drug Administration (2014) Food and Drug Administration labeling information: revised Multaq label, prepared by U.S Food and Drug Administration (FDA). http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022425s025lbl.pdf. Accessed 6 Jan 2017
- ICH Q1A (R2) (2003) Stability testing of new drug substances and products. In: International conference on harmonization, Geneva, SwitzerlandGoogle Scholar
- ICH Q2 (R1) (2005) Validation of analytical procedures: text and methodology. In: International conference on harmonization, Geneva, SwitzerlandGoogle Scholar
- Landge SB, Jadhav SA, Nimbalkara KP, Mali AC, Mathad VT (2013) Stability indicating RP-HPLC method for the determination of dronedarone hydrochloride and its potential process-related impurities in bulk drug and pharmaceutical dosage form. Am J Anal Chem 4:323–335. https://doi.org/10.4236/ajac.2013.46041 CrossRefGoogle Scholar
- Le Heuzey J-Y, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy J-M (2010) A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 21:597–605. https://doi.org/10.1111/j.1540-8167.2010.01764 CrossRefPubMedGoogle Scholar
- Mendes C, Buttchevitz A, Kruger JH, Kratz JM, Simões CMO, Benedet PO, Oliveira PR, Silva MAS (2016) Inclusion complexes of hydrochlorothiazide and β-cyclodextrin: physicochemical characteristics, in vitro and in vivo studies. Eur J Pharm Sci 83:71–78. https://doi.org/10.1016/j.ejps.2015.12.015 CrossRefPubMedGoogle Scholar
- Nogueira DR, Mitjans M, Infante MR, Vinardell MP (2011) Comparative sensitivity of tumor and non-tumor cell lines as a reliable approach for in vitro cytotoxicity screening of lysine-based surfactants with potential pharmaceutical applications. Int J Pharm 420:51–58. https://doi.org/10.1016/j.ijpharm.2011.08.020 CrossRefPubMedGoogle Scholar
- Rowe RC, Sheskey PJ, Quinn ME (2009) Handbook of pharmaceutical excipients, 6th edn. Pharmaceutical Press and American Pharmacists Association, London, pp 888–889Google Scholar
- Shabir GA (2003) Validation of high-performance liquid chromatography methods for pharmaceutical analysis. Understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference on Harmonization. J Chromatogr A 987:57–66. https://doi.org/10.1016/s0021-9673(02)01536-4 CrossRefPubMedGoogle Scholar
- The United States Pharmacopeial Convention (2016) The United States Pharmacopeia and The National Formulary, USP 39-NF 34, RockvilleGoogle Scholar
- Xie C, Yang S, Zhong D, Dai X, Chen X (2011) Simultaneous determination of dronedarone and its active metabolite debutyldronedarone in human plasma by liquid chromatography–tandem mass spectrometry: application to a pharmacokinetic study. J Chromatogr B 879:3071–3075. https://doi.org/10.1016/j.jchromb.2011.09.004 CrossRefGoogle Scholar
- Yoshioka S, Stella VJ (2002) Stability of drugs and dosage forms. Kluwer Academic Publishers, New YorkGoogle Scholar